Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 391

Sort by

Sort Order Select

Journal Articles

The bidirectional increased risk of B-cell lymphoma and T-cell lymphoma

Dai Chihara, Graça M. Dores, Christopher R. Flowers, Lindsay M. Morton

Blood (2021) 138 (9): 785–789.

https://doi.org/10.1182/blood.2020010497

Published: 2021

Includes: Supplemental data

Journal Articles

The rise of a new “great teacher”

Amanda B. McBride, Pierluigi Porcu

Blood (2021) 138 (3): 205–206.

https://doi.org/10.1182/blood.2021011754

Published: 2021

Journal Articles

Outcomes and prognostic factors in angioimmunoblastic T-cell lymphoma: final report from the international T-cell Project

Ranjana H. Advani, Tetiana Skrypets, Monica Civallero, Michael A. Spinner, Martina Manni, Won Seog Kim, Andrei R. Shustov, Steven M. Horwitz, Felicitas Hitz, Maria Elena Cabrera, Ivan Dlouhy, José Vassallo, Stefano A. Pileri, Giorgio Inghirami, Silvia Montoto, Umberto Vitolo, John Radford, Julie M. Vose, Massimo Federico

Blood (2021) 138 (3): 213–220.

https://doi.org/10.1182/blood.2020010387

Published: 2021

Includes: Supplemental data

Journal Articles

Circulating angioimmunoblastic T-cell lymphoma cells

Konstantinos Liapis, Georgios Paterakis

Blood (2020) 135 (18): 1607.

https://doi.org/10.1182/blood.2020004944

Published: 2020

Journal Articles

A Phase II Study of Nivolumab in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma

N. Nora Bennani, MD, Levi D Pederson, Pamela Atherton, Ivana Micallef, MD, Joseph P. Colgan, MD, Gita Thanarajasingam, MD, Grzegorz Nowakowski, MD, Thomas E. Witzig, MD, Andrew L. Feldman, MD, Stephen M Ansell, MD

Blood (2019) 134 (Supplement_1): 467.

https://doi.org/10.1182/blood-2019-126194

Published: 2019

Journal Articles

A Phase 2 Study of the Dual SYK/JAK Inhibitor Cerdulatinib Demonstrates Good Tolerability and Clinical Response in Relapsed/Refractory Peripheral T-Cell Lymphoma and Cutaneous T-Cell Lymphoma

Steven M. Horwitz, MD, Tatyana A. Feldman, MD, Brian T. Hess, MD, Michael S. Khodadoust, MD PhD, Youn H. Kim, MD, Javier Munoz, MD MS, FACP, Manish R. Patel, MD, Tycel J. Phillips, MD, Stephen D. Smith, MD, Sonali M. Smith, MD, Ryan A. Wilcox, MD PhD, Matt R. Birrell, Janet M. Leeds, PhD, Pamela B. Conley, PhD, Glenn C. Michelson, MD, Gregory P. Coffey, PhD, John T. Curnutte, MD PhD, Paul A. Hamlin, MD

Blood (2019) 134 (Supplement_1): 466.

https://doi.org/10.1182/blood-2019-123986

Published: 2019

Journal Articles

Proof of Concept for Tipifarnib in Relapsed or Refractory Angioimmunoblastic T-Cell Lymphoma (AITL) and CXCL12+ Peripheral T-Cell Lymphoma (PTCL): Preliminary Results from an Open-Label, Phase 2 Study

Blood (2019) 134 (Supplement_1): 468.

https://doi.org/10.1182/blood-2019-128513

Published: 2019

Journal Articles

Safety and Anti-Tumor Activity of CD5 CAR T-Cells in Patients with Relapsed/Refractory T-Cell Malignancies

LaQuisa C. Hill, MD, Rayne H. Rouce, MD, Tyler S. Smith, Lina Yang, PhD, Madhuwanti Srinivasan, Huimin Zhang, BS, Silvana Perconti, Birju Mehta, MS, BS, Olga Dakhova, Josalind Randall, Bambi J. Grilley, RPh, Helen E. Heslop, MD DSc, Malcolm K. Brenner, MD PhD, Maksim Mamonkin, PhD

Blood (2019) 134 (Supplement_1): 199.

https://doi.org/10.1182/blood-2019-129559

Published: 2019

Journal Articles

VAV1 Mutations Contributes to the Development of T-Cell Malignancies in Mice

Kota Fukumoto, MD, Mamiko Sakata-Yanagimoto, MD PhD, Manabu Fujisawa, MD, Tatsuhiro Sakamoto, MD PhD, Tran B. Nguyen, Sakurako Suma, MD, Hiroaki Miyoshi, MD PhD, Koichi Ohshima, MD PhD, Keisuke Kataoka, MD PhD, Seishi Ogawa, MD PhD, Shigeru Chiba, MD PhD

Blood (2019) 134 (Supplement_1): 300.

https://doi.org/10.1182/blood-2019-124591

Published: 2019

Journal Articles

Clinical Characteristic and Survival Outcome of Peripheral T Cell Lymphoma in a Chinese Population

Wenyu Li, MD PhD, Ling Huang, MD, Xinmiao Jiang, MD, Xiaojuan Wei, Hanguo Guo, Liu Sichu, MD, Chen Feili, MD, Zhanli Liang

Blood (2019) 134 (Supplement_1): 5271.

https://doi.org/10.1182/blood-2019-129552

Published: 2019

Journal Articles

"Real-World" Peripheral T-Cell Lymphomas Experience in Portugal: Is There Reason for Optimism?

Ivan Dlouhy, Rita Gavancha, MD, Inês Coelho, MD, Catalina Gomez, MD, Inês Barbosa, MD, Susana Carvalho, MD, Maria Ceu Trindade, MD, Ana Filipa Moita, Gonçalo Esteves, MD, Paula Gameiro, Jose Cabecadas, Maria Silva, MD

Blood (2019) 134 (Supplement_1): 5287.

https://doi.org/10.1182/blood-2019-124485

Published: 2019

Journal Articles

A Comprehensive Analysis of Rhoa Mutation Positive and Negative Angioimmunoblastic T-Cell Lymphomas By Targeted Deep Sequencing, Expression Profiling, and Single Cell Digital Image Analysis

Alexandra Butzmann, MD, Kaushik Sridhar, MS, Diwash Jangam, PhD, Jyoti Kumar, MDMS, Malaya K Sahoo, PhD, Nahid Shahmarvand, MD, Roger A Warnke, MD, Elumalai Rangasamy, PhD, Benjamin A Pinsky, MD PhD, Robert S. Ohgami, MD PhD

Blood (2019) 134 (Supplement_1): 5228.

https://doi.org/10.1182/blood-2019-129560

Published: 2019

Journal Articles

Relapsed or Refractory Angioimmunoblastic T-Cell Lymphoma (r/r AITL) North Asian Patients after Failure of First-Line Therapy: A Pooled Analysis of Two Pralatrexate Studies

Jun Zhu, MD, Ee-Min Yeoh, BSc, Yoshinobu Maeda, MD PhD

Blood (2019) 134 (Supplement_1): 5290.

https://doi.org/10.1182/blood-2019-124080

Published: 2019

Journal Articles

Central Nervous System Involvement in Peripheral T-Cell Lymphoma

Sangeetha Gandhi, MBBS, N. Nora Bennani, MD, Sonia Fortin, Thomas M. Habermann, MD, Patrick Johnston, MD, James R. Cerhan, MD PhD, Kay M. Ristow, BS, Carrie A. Thompson, MD, Grzegorz Nowakowski, MD, Yi Lin, MD PhD, Jose C Villasboas, MD, Luis Porrata, MD, Thomas E. Witzig, MD, Ivana Micallef, MD, David J Inwards, MD, Stephen M Ansell, MD PhD, Jonas Paludo, MD

Blood (2019) 134 (Supplement_1): 5293.

https://doi.org/10.1182/blood-2019-131965

Published: 2019

Journal Articles

Optimize the Patient to Optimize the Therapy: Role of Prephase Cyclophosphamide in Aggressive Lymphoma

Nabin Karki, MBBS, Vamsi Kota, MBBS, Katherine Saunders, PharmD, Cara Iacobellis, PharmD, Anand Jillella, MD, Germame Ajebo, MD, Locke J. Bryan, MD

Blood (2019) 134 (Supplement_1): 5294.

https://doi.org/10.1182/blood-2019-129644

Published: 2019

Journal Articles

Potential Metabolites with Diagnostic Value in Plasma for Angioimmunoblastic T-Cell Lymphoma By LC-MS Based Untargeted Metabonomics Study

Haiyan Yang, Tao Lei, Cong Li, Haifeng Yu, Zhongjian Chen

Blood (2019) 134 (Supplement_1): 5234.

https://doi.org/10.1182/blood-2019-129897

Published: 2019

Journal Articles

Final Results of a Phase II Biomarker-Driven Study of Ruxolitinib in Relapsed and Refractory T-Cell Lymphoma

Blood (2019) 134 (Supplement_1): 4019.

https://doi.org/10.1182/blood-2019-125017

Published: 2019

Journal Articles

Clinicopathological Analysis of "Other Iatrogenic Immunodeficiency-Associated Lymphoproliferative Disorders" Reveals a Favorable Outcome Independent of the Effectiveness of Methotrexate Discontinuation in Autoimmune Disease Patients

Daisuke Kaji, MD, Manabu Kusakabe, MD PhD, Mamiko Sakata-Yanagimoto, MD PhD, Yasuhito Suehara, MD, Keiichiro Hattori, MD PhD, Yasunori Ota, MD PhD, Mitsuhiro Yuasa, MD, Kosei Kageyama, MD, Yuki Taya, MD PhD, Shinsuke Takagi, Hisashi Yamamoto, MD PhD, Yuki Asano-Mori, MD PhD, Naoyuki Uchida, MD PhD, Atsushi Wake, MD PhD, Shuichi Taniguchi, MD PhD, Go Yamamoto, MD PhD, Shigeru Chiba, MD PhD

Blood (2019) 134 (Supplement_1): 4128.

https://doi.org/10.1182/blood-2019-127521

Published: 2019

Journal Articles

Peripheral Blood Involvement By Flow Cytometry As a Prognostic Factor in Aggressive T Cell Lymphomas Following Autologous Stem Cell Transplantation

Namrata S Chandhok, MD, Scott F. Huntington, MD MPH, Iris Isufi, MD, Lohith Gowda, MD MRCP, Mina L Xu, MD, Noffar Bar, MD, Stuart Seropian, MD, Francine M. Foss, MD

Blood (2019) 134 (Supplement_1): 4055.

https://doi.org/10.1182/blood-2019-128888

Published: 2019

Journal Articles

Early Complete Remission By Functional Imaging and Intensified Frontline Therapy Are Associated with an Improved Clinical Outcome in Patients with Newly Diagnosed T-Cell Lymphoma- a Single Center Experience

Suchitra Sundaram, MD, Matthew Gravina, MD, Pallawi Torka, MD, Kristopher Attwood, PhD, Francisco J. Hernandez-Ilizaliturri, MD

Blood (2019) 134 (Supplement_1): 4058.

https://doi.org/10.1182/blood-2019-132244

Published: 2019

NARROW

The bidirectional increased risk of B-cell lymphoma and T-cell lymphoma

The rise of a new “great teacher”

Outcomes and prognostic factors in angioimmunoblastic T-cell lymphoma: final report from the international T-cell Project

Circulating angioimmunoblastic T-cell lymphoma cells

A Phase II Study of Nivolumab in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma

A Phase 2 Study of the Dual SYK/JAK Inhibitor Cerdulatinib Demonstrates Good Tolerability and Clinical Response in Relapsed/Refractory Peripheral T-Cell Lymphoma and Cutaneous T-Cell Lymphoma

Proof of Concept for Tipifarnib in Relapsed or Refractory Angioimmunoblastic T-Cell Lymphoma (AITL) and CXCL12+ Peripheral T-Cell Lymphoma (PTCL): Preliminary Results from an Open-Label, Phase 2 Study

Safety and Anti-Tumor Activity of CD5 CAR T-Cells in Patients with Relapsed/Refractory T-Cell Malignancies

VAV1 Mutations Contributes to the Development of T-Cell Malignancies in Mice

Clinical Characteristic and Survival Outcome of Peripheral T Cell Lymphoma in a Chinese Population

"Real-World" Peripheral T-Cell Lymphomas Experience in Portugal: Is There Reason for Optimism?

A Comprehensive Analysis of Rhoa Mutation Positive and Negative Angioimmunoblastic T-Cell Lymphomas By Targeted Deep Sequencing, Expression Profiling, and Single Cell Digital Image Analysis

Relapsed or Refractory Angioimmunoblastic T-Cell Lymphoma (r/r AITL) North Asian Patients after Failure of First-Line Therapy: A Pooled Analysis of Two Pralatrexate Studies

Central Nervous System Involvement in Peripheral T-Cell Lymphoma

Optimize the Patient to Optimize the Therapy: Role of Prephase Cyclophosphamide in Aggressive Lymphoma

Potential Metabolites with Diagnostic Value in Plasma for Angioimmunoblastic T-Cell Lymphoma By LC-MS Based Untargeted Metabonomics Study

Final Results of a Phase II Biomarker-Driven Study of Ruxolitinib in Relapsed and Refractory T-Cell Lymphoma

Clinicopathological Analysis of "Other Iatrogenic Immunodeficiency-Associated Lymphoproliferative Disorders" Reveals a Favorable Outcome Independent of the Effectiveness of Methotrexate Discontinuation in Autoimmune Disease Patients

Peripheral Blood Involvement By Flow Cytometry As a Prognostic Factor in Aggressive T Cell Lymphomas Following Autologous Stem Cell Transplantation

Early Complete Remission By Functional Imaging and Intensified Frontline Therapy Are Associated with an Improved Clinical Outcome in Patients with Newly Diagnosed T-Cell Lymphoma- a Single Center Experience

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only